GlucoTrack Shares Company Status Update with Shareholders An update from GlucoTrack (GCTK) is now available. Glucotrack, Inc., a company incorporated in Delaware, recently shared a slide presentation with …
GlucoTrack Elevates Board and Streamlines Governance Processes An announcement from GlucoTrack (GCTK) is now available. Glucotrack, Inc. has enhanced its Board of Directors by appointing Andrew K. Balo, a seaso…
GLUCOTRACK ANNOUNCES THE APPOINTMENT OF ANDY BALO TO BOARD OF DIRECTORS Diabetes industry veteran joins Glucotrack's Board to support bringing novel continuous blood glucose monitoring technology to people with diabetes
GlucoTrack Advances with Successful Preclinical Study GlucoTrack (GCTK) has issued an update. Glucotrack, Inc. has announced the successful completion of a 60-day preclinical study on epidural glucose …
GLUCOTRACK REPORTS SUCCESSFUL COMPLETION OF FIRST REPORTED LONG-TERM PRECLINICAL STUDY OF ITS EPIDURAL GLUCOSE MONITORING SENSOR Completion of the novel epidural continuous glucose monitoring study confirms its potential for providing simplified disease management for patients with painful diabetic neuropathy
GLUCOTRACK TO PRESENT IN THE JUNE 2024 SIDOTI SMALL CAP CONFERENCE Rutherford, NJ, June 10, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the Sidoti Small Cap Investor Conference. Paul V. Goode, CEO of Glucotrack, will present on Wednesday, Jetzt den vollständigen Artikel lesen
GLUCOTRACK TO PRESENT IN THE JUNE 2024 SIDOTI SMALL CAP CONFERENCE Rutherford, NJ, June 10, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the Sidoti Small Cap Investor Conference.
GLUCOTRACK ANNOUNCES 90-DAY PRECLINICAL STUDY RESULTS THAT DEMONSTRATE SUSTAINED ACCURACY OF ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR | GCTK Stock News Glucotrack''s CBGM shows 4.7% MARD accuracy in a 90-day preclinical study, outperforming existing monitors. Human trials to begin soon. Read more for details.
GLUCOTRACK ANNOUNCES 90-DAY PRECLINICAL STUDY RESULTS THAT DEMONSTRATE SUSTAINED ACCURACY OF ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITOR Highly accurate continuous blood glucose monitor demonstrates Mean Absolute Relative Difference (MARD) of 4.7% at Day 90
GCTK Stock Earnings: GlucoTrack Reported Results for Q1 2024 GlucoTrack (NASDAQ: GCTK ) just reported results for the first quarter of 2024. GlucoTrack reported earnings per share of -12 cents. The company did not report any revenue for the quarter. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now. The post GCTK Stock Earnings: GlucoTrack Reported Results for Q1 2024 appeared first on InvestorPlace .